A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors
Zai Lab (Shanghai) Co., Ltd.
Summary
A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors
Description
This is an open-label, multiple-center, phase 1b/2 study of ZL-1310 in selected solid tumors.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Signed informed consent * Adult men and women ≥18 years of age * Participants must have histologically confirmed, locally advanced or metastatic NeuroEndocrine Carcionomas (NEC), and must have experienced disease progression on or after platinum-based therapy * Participants must be willing to undergo a tumor biopsy or must provide archived tumor tissue sample * Participants must have at least one measurable target lesion as defined by RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy ≥ 3 months Exclusion Criteria: *…
Interventions
- DrugZL-1310
drug ZL-1310
Locations (21)
- Zai Lab Site 2001San Francisco, California
- Zai Lab Site 2015Peoria, Illinois
- Zai Lab Site 2013Detroit, Michigan
- Zai Lab Site 2002New York, New York
- Zai Lab Site 2024Cleveland, Ohio
- Zai Lab Site 2004Philadelphia, Pennsylvania